UK Public Assessment Report
|
|
- Tracy McBride
- 7 years ago
- Views:
Transcription
1 MAX STRENGTH DECONGESTANT TABLETS (PHENYLEPHRINE HYDROCHLORIDE) PL 16028/0114 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Summary of Product Characteristics Page 15 Product Information Leaflet Page 18 Labelling Page 20 1
2 MAX STRENGTH DECONGESTANT TABLETS (PHENYLEPHRINE HYDROCHLORIDE) PL 16028/0114 LAY SUMMARY The Medicines and Healthcare products Regulatory Agency (MHRA) granted Galpharm Healthcare Limited a Marketing Authorisation (licence) for the medicinal product Max Strength Decongestant Tablets (PL 16028/0114) on 6 th February This is a General Sales List medicine (GSL) used for the relief of nasal congestion. Max Strength Decongestant Tablets contain the active ingredient, phenylephrine hydrochloride, which is a nasal decongestant and helps to open up the nasal airways allowing you to breathe more easily. The tablets are used to relieve a stuffy or blocked nose caused by colds and hayfever. No new or unexpected safety concerns arose from this application and it was therefore judged that the benefits of taking Max Strength Decongestant Tablets outweigh the risk; hence a Marketing Authorisation has been granted. 2
3 MAX STRENGTH DECONGESTANT TABLETS (PHENYLEPHRINE HYDROCHLORIDE) PL 16028/0114 SCIENTIFIC DISCUSSION TABLE OF CONTENTS Introduction Page 4 Pharmaceutical assessment Page 5 Preclinical assessment Page 8 Clinical assessment Page 9 Overall conclusion and risk benefit assessment Page 13 3
4 INTRODUCTION Based on the review of the data on quality, safety and efficacy, the MHRA granted Galpharm Healthcare Limited a Marketing Authorisation for the medicinal product Max Strength Decongestant Tablets (PL 16028/0114) on 6 th February This is a GSL medicine indicated for the treatment of nasal congestion. The application was submitted as a standard national, abridged, bibliographic application, for an active of well-established use, according to Article 10(a) of Directive 2001/83/EC, as amended. Each Max Strength Decongestant Tablet contains 12.2mg of the active ingredient, phenylephrine hydrochloride. Phenylephrine hydrochloride (PE) is a post-synaptic α-receptor agonist, with low cardioselective β-receptor affinity. It has a recognised decongestant activity, by vasoconstriction, to reduce oedema of the nasal mucosa. α-adrenergic receptors are found on pre- and post-capillary blood vessels in the nasal mucosa, stimulation of which causes constriction of vascular smooth muscle. As a consequence, nasal blood flow is reduced leading to a reduction in nasal mucosal swelling. The tablets are indicated to relieve nasal congestion associated with colds and hayfever. 4
5 PHARMACEUTICAL ASSESSMENT ACTIVE SUBSTANCE Phenylephrine hydrochloride Nomenclature: INN: Phenylephrine hydrochloride Chemical name: (1R)-1-(3-hydroxyphenyl)-2-(methyl amino) ethanol hydrochloride Structure: Molecular formula: C 9 H 13 NO 2, HCl Molecular weight: CAS No: Physical form: Solubility: A white or almost white crystalline powder Freely soluble in water and ethanol The active substance, phenylephrine hydrochloride, is the subject of a European Pharmacopeia (EP) monograph. All aspects of the manufacture and control of phenylephrine hydrochloride are supported by an EDQM Certificate of Suitability. This certificate is accepted as confirmation of the suitability of phenylephrine hydrochloride for inclusion in this medicinal product. Appropriate stability data have been generated for phenylephrine hydrochloride stored in the proposed packaging. These data demonstrate the stability of the active substance and a suitable retest period has been set based on the data. The certificate of suitability confirms a retest period of 5 years if the material is stored at a temperature not exceeding 25 C in a container consisting of two polyethylene bags placed in a fibre drum or in a polyethylene bottle. DRUG PRODUCT Description & Composition The drug product is presented as round, bi-convex, red film-coated tablets containing 12.18mg of the active substance phenylephrine hydrochloride. Other ingredients consist of pharmaceutical excipients, namely lactose monohydrate, microcrystalline cellulose, powdered cellulose, magnesium stearate, sodium starch glycollate, and colloidal anhydrous silica making up the tablet core; titanium dioxide (E171), macrogol 4000, eudragit E 12.5, and hypromellose making up the film coating; and hypromellose, macrogol 4000, titanium dioxide, talc, azorubin, brilliant ponceau, red lake (E124), and polysorbate 80 making up the colour coating. Appropriate justification for the inclusion of each excipient has been provided. 5
6 All excipients used comply with their respective European Pharmacopoeia monographs, apart from azorubin, brilliant ponceau, and red lake (E124) which comply with EU guidelines. Satisfactory Certificates of Analysis have been provided for all excipients. The magnesium stearate is of vegetable origin. The only excipient used that contains material of animal or human origin is lactose monohydrate. The applicant has provided a declaration that milk used in the production of lactose monohydrate is sourced from healthy animals under the same conditions as milk collected for human consumption. There were no novel excipients used and no overages. Pharmaceutical development Details of the pharmaceutical development of the drug product have been supplied and are satisfactory. Manufacture A description and flow-chart of the manufacturing method has been provided. In-process controls have been provided and are appropriate considering the nature of the product and the method of manufacture. Process validation studies have been conducted and are satisfactory. Finished product specification The finished product specification is satisfactory. Acceptance limits have been justified with respect to conventional pharmaceutical requirements and, where appropriate, safety. Test methods have been described and have been adequately validated, as appropriate. Batch data have been provided and comply with the release specification. Certificates of Analysis have been provided for any reference standards and working standards used. Container Closure System The tablets are packed in PVC (polyvinyl chloride) / PVDC (polyvinylidene chloride) / aluminium foil blisters, which are placed with the PIL into cardboard outer cartons. The product is packaged in carton pack sizes of 12 or 24 tablets. Specifications and Certificates of Analysis for all packaging components used have been provided. These are satisfactory. All primary product packaging complies with EU legislation, Directive 2002/72/EC (as amended), and is suitable for contact with foodstuffs. Stability Finished product stability studies have been conducted in accordance with current guidelines and results were within the proposed specification limits. Based on the results, a shelf-life of 2 years has been set, which is satisfactory. The storage instructions are Do not store above 25 C and Store in the original package. 6
7 Bioequivalence Study There was no bioequivalence study carried out to support this application. The legal basis of the application is that it is bibliographic; therefore, a bioequivalence study is not required. Expert Report A satisfactory expert report is provided, and has been prepared by an appropriately qualified expert. An appropriate CV for the expert has been supplied. Product Information The approved SmPC, leaflet, and labelling are satisfactory. Conclusion All pharmaceutical issues have been resolved and the quality grounds for this application are considered adequate. A Marketing Authorisation may be granted. 7
8 PRECLINICAL ASSESSMENT The application was submitted as a bibliographic application, for an active of wellestablished use, according to Article 10(a) of Directive 2001/83/EC (as amended). No new preclinical data have been supplied with this application and none are required for an application of this type. A preclinical expert report has been written by a suitably qualified person and is satisfactory. 8
9 CLINICAL ASSESSMENT INDICATIONS Max Strength Decongestant Tablets are indicated for the relief of nasal congestion associated with colds and hayfever. The indication is consistent with other products containing phenylephrine hydrochloride as an active substance and is supported by the literature. POSOLOGY AND METHOD OF ADMINISTRATION Adults and children over 12 years: one tablet, up to four times daily. Children under 12 years: not recommended Elderly: There is no need for dosage reduction in the elderly. The dose is appropriate. TOXICOLOGY No new data have been submitted and none are required for this type of application. LEGAL STATUS The legal status of the product is GSL. The current legal status of phenylephrine restricts the maximum single dose to 10mg as a general sale list product mg of phenylephrine hydrochloride is equivalent to 10mg of free phenylephrine and therefore the product falls within the current parameters for GSL status. CLINICAL PHARMACOLOGY Pharmacodynamics Phenylephrine is a post-synaptic α-receptor agonist, with low cardioselective β- receptor affinity. It is has a recognised decongestant activity, by vasoconstriction to reduce oedema of the nasal mucosa. No additional pharmacodynamic studies have been presented. Pharmacokinetics Phenylephrine has low bioavailability (~38%) from the gastrointestinal tract owing to variable absorption and first-pass metabolism. There is significant biotransformation in the intestinal wall. However, phenylephrine is active as a decongestant by the oral route, the drug distributes through the systemic circulation to the vascular bed of the nasal mucosa. Bioequivalence Study No bioequivalence studies have been conducted as the proposed product is indicated for the relief of symptoms in non-serious, self-limiting conditions and it is associated with a low incidence of serious adverse events at the dose proposed. The absence of a bioequivalence study is justified both in terms of the active substance and the medicinal product. Differences in bioavailability are unlikely to result in therapeutic inequivalencies. 9
10 EFFICACY No new data are submitted and none are required for this type of application. Phenylephrine is a decongestant which acts by vasoconstriction to reduce oedema and swelling of the nasal mucosa. By this means, nasal discharge may be reduced and obstruction associated with colds and influenza may be relieved. Despite the paucity of data on efficacy of oral phenylephrine, studies showing measurable reductions in nasal airway resistance have been provided. These data are sufficient for a product of this nature and demonstrates both activity and efficacy for its intended indications. SAFETY The applicant has not conducted safety studies in support of this submission. At sufficiently large doses; enough to result in nasal decongestion, phenylephrine has the potential to affect other vascular beds and exert a vasoconstrictor effect, therefore resulting in hypertension and bradycardia. This is because phenylephrine acts mainly as an α 1 -agonist and has only weak β-adrenoreceptor activity. The α 1 pressor action causes reflex bradycardia and therefore overall contractile force of the heart remains the same. Phenylephrine has little or no direct effect on the β 1 receptors in the heart which control heart rate, conduction velocity and contractile force and therefore arrhythmias are unlikely to occur following phenylephrine administration particularly at low dosage and over short treatment durations. Adverse events are well characterised and correlate with the pharmacology of phenylephrine. Reports have included tachycardia, cardiac arrhythmias, palpitations, hypertension, nausea, vomiting, headache and urinary retention in men. A Drug Analysis Print (DAP) was provided by the applicant covering a 42-year period from 01 July 1963 to 30 October 2005, during which time only 62 adverse drug reactions (ADRs) were attributed to single-ingredient phenylephrine products. The most frequently reported ADRs were categorised as: rhinitis (n = 6), drug dependence (n = 6), vomiting (n=3), malaise (n =3) nausea (n = 2), tachycardia (n= 2), dizziness (n = 2), rash (n =2), hypertension (n = 2). All other reported ADRs were singular events. No fatalities were reported during this period for single product phenylephrine. Three deaths were reported with multi-ingredient products, but the case reports were not available. Large excesses of phenylephrine are required to cause increases in blood pressure; up to 120mg. 50mg of phenylephrine (5 tablets of the proposed product) as a single dose has been documented as the minimum amount required to cause an increase in blood pressure. 10mg phenylephrine was found not to affect blood pressure. PE does not sedate or impair motor skills or coordination and is not known to affect the ability of consumers to drive or operate machinery. Effects on cognition are not significant. Given the wide exposure of this product and the long history of use of oral phenylephrine, the safety record for phenylephrine is established, documented and reassuringly predictable. When used at recommended doses for short periods, phenylephrine hydrochloride mg tablets are considered to be suitable for selfmedication in order to treat the nasal congestion associated with the common cold and hayfever. 10
11 ABUSE AND MISUSE OF PHENYLEPHRINE Abuse Phenylephrine is much less readily converted to substances of abuse such as methamphetamine than other sympathomimetics such as pseudoephedrine. Phenylephrine differs from endogenous adrenaline in lacking a hydroxyl group in the 4-position. Because of its direct activity, it does not cause release of endogenous noradrenaline, and is therefore less likely to cause central nervous system stimulating effects such as restlessness, irritability, insomnia and anxiety. Although it is possible to convert phenylephrine to methamphetamine, it is a difficult process and would require much greater knowledge and equipment than the relatively simple conversion of pseudoephedrine to methamphetamine. Published case reports of intentional and persistent abuse by determined individuals are very rare. Phenylephrine, at the recommended dose for phenylephrine hydrochloride mg tablets, has no significant central nervous system stimulatory effects. Phenylephrine is an unlikely substance of recreational abuse. The potential for phenylephrine abuse using single-ingredient products such as phenylephrine hydrochloride mg tablets is considered unlikely. Misuse Accidental misuse of this product is not reported by the applicant. There are a number of single and fixed dose combination phenylephrine products already available to the consumer and an associated, inherent risk of escalating doses of phenylephrine. This is less of an issue due to the wide safety window and high doses of phenylephrine required to cause unwanted effects. There are 6 reported cases of dependence, but data on these cases was not made available. Oral decongestants do not appear to cause rebound congestion, unlike topical products such as oxymetazoline. The maximum recommended duration of treatment is 7 days. EXPERT REPORT A satisfactory expert report is provided, and has been prepared by an appropriately qualified expert. An appropriate CV for the expert has been supplied. PRODUCT INFORMATION: Summary of Product Characteristics (SmPC) The final SmPC is satisfactory. Patient Information Leaflet (PIL) The PIL is in line with the approved SmPC and is satisfactory. Labelling Colour mock-ups of the labelling have been provided. The labelling is satisfactory. 11
12 DISCUSSION AND CONCLUSION This is a bibliographic application. No clinical study has been undertaken, or was necessary, to demonstrate the efficacy of the product. The bibliography is supportive of the efficacy of the active ingredient and provides adequate information regarding safety. Phenylephrine has been licensed for the treatment of nasal congestion for much more than 10 years and its well established use is accepted. All issues have been adequately addressed by the applicant. Sufficient clinical information has been submitted to support this application. When used as indicated, Max Strength Decongestant Tablets have a favourable benefit-to-risk ratio. Therefore, a Marketing Authorisation may be granted on medical grounds. 12
13 OVERALL CONCLUSION AND RISK BENEFIT ASSESSMENT QUALITY The important quality characteristics of Max Strength Decongestant Tablets are well defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance. PRECLINICAL No new preclinical data were submitted and none are required for an application of this type. Single and repeat dose animal model data submitted is both limited and old (as far back as 1946), reflecting the historic nature of the active substance. The animal data appears consistent with effects seen in patients. There were no carcinogenic or mutagenic effects seen in animal models. EFFICACY No new data are submitted and none are required for this type of application. Medicinal products containing phenylephrine have been available in the UK for much more than ten years. Their use is well established with recognised efficacy and acceptable safety. The published literature supports the efficacy of phenylephrine hydrochloride as a nasal decongestant and identifies no new safety issues or concerns. No new or unexpected safety concerns arise from this application. PRODUCT LITERATURE The approved SmPC, PIL and labelling are satisfactory. A package leaflet has been submitted to the MHRA along with results of consultations with target patient groups ("user testing"), in accordance with Article 59 of Council Directive 2001/83/EC. The results indicate that the package leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains. The approved labelling artwork complies with statutory requirements. In line with current legislation, the name of the product in Braille appears on the outer packaging and sufficient space has been included for a standard UK pharmacy dispensing label. RISK BENEFIT ASSESSMENT The quality of the product is acceptable and no new preclinical or clinical safety concerns have been identified. Extensive clinical experience with phenylephrine hydrochloride is considered to have demonstrated the therapeutic value of the active substance. The risk: benefit is, therefore, considered to be positive. 13
14 MAX STRENGTH DECONGESTANT TABLETS (PHENYLEPHRINE HYDROCHLORIDE) PL 16028/0114 STEPS TAKEN FOR ASSESSMENT 1 The MHRA received the marketing authorisation application on 18 th June Following standard checks and communication with the applicant the MHRA considered the application valid on 2 nd August Following assessment of the application the MHRA requested further information relating to the quality dossier on 29 th August The applicant responded to the MHRA s request, providing further information for the quality sections on 8 th November The application was determined on 6 th February
15 SUMMARY OF PRODUCT CHARACTERISTICS The UK Summary of Product Characteristics (SPC) for Max Strength Decongestant Tablets is as follows: 1 NAME OF THE MEDICINAL PRODUCT Phenylephrine HCl mg Tablets Max Strength Decongestant Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Phenylephrine Hydrochloride 12.18mg For excipients, see PHARMACEUTICAL FORM Round, bi-convex, red film coated tablets. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications For the relief of nasal congestion associated with colds and hayfever. 4.2 Posology and method of administration Adults and children over 12 years: One tablet, up to four times daily. Children under 12 years: Not recommended. Elderly: There is no need for dosage reduction in the elderly. 4.3 Contraindications Hypersensitivity to any of the ingredients. Avoid in patients with cardiovascular disease, high blood pressure, diabetes mellitus, closed angle glaucoma, hyperthyroidism, prostatic enlargement and phaeochromocytoma. Patients being treated with monoamine oxidase inhibitors or within 14 days of ceasing such treatment (see section 4.5). 4.4 Special warnings and precautions for use This medicine should be used with caution in patients with occlusive vascular disease including Raynaud's Phenomenon. Patients with rare hereditory problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. The label will state: Do not take for more than 7 days, unless your doctor agrees. If symptoms do not go away talk to your doctor. Keep all medicines out of the reach and sight of children. Warning: Do not exceed the stated dose. 4.5 Interaction with other medicinal products and other forms of interaction Should not be given to patients being treated with monoamine oxidase inhibitors or within 14 days of stopping such treatment. May enhance the effects of anticholinergic drugs such as tricyclic antidepressants. May increase the possibility of arrhythmias in digitalised patients. May enhance the cardiovascular effects of other sympathomimetic amines (e.g. decongestants). This medicine should not be taken together with vasodilators or Beta-blockers. 15
16 4.6 Pregnancy and lactation The safety of this medicine during pregnancy and lactation has not been established but in view of a possible association of foetal abnormalities with first trimester exposure to phenylephrine, the use of the product during pregnancy should be avoided. In addition, because phenylephrine may reduce placental perfusion, the product should not be used in patients with a history of pre-eclampsia. In view of the lack of data on the use of phenylephrine during lactation, this medicine should not be used during breast feeding. 4.7 Effects on ability to drive and use machines No adverse effects known. 4.8 Undesirable effects Adverse effects may include tachycardia, cardiac arrhythmias, palpitations, hypertension, nausea, vomiting, headache and occasionally urinary retention in males. 4.9 Overdose Symptoms of overdosage include irritability, restlessness, palpitations, hypertension, difficulty in micturition, nausea, vomiting, thirst and convulsions. In severe overdosage gastric lavage and aspiration should be performed. Symptomatic and supportive measures should be undertaken, particularly with regard to cardiovascular and respiratory systems. Convulsions should be controlled with intravenous diazepam. Chlorpromazine may be used to control marked excitement and hallucinations. Severe hypertension may need to be treated with an alpha-adrenoreceptor blocking drug, such as phentolamine. A beta blocker may be required to control cardiac arrhythmias. 5 PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Phenylephrine is a sympathomimetic agent with mainly direct effects on adrenergic receptors. It has predominantly alpha adrenergic activity and is without stimulating effects on the central nervous system. The sympathomimetic effect of phenylephrine produces vasoconstriction which in turn relieves nasal congestion. 5.2 Pharmacokinetic properties Phenylephrine is readily absorbed after oral administration but is subject to extensive presystemic metabolism, much of which occurs in the enterocytes. As a consequence, systemic bioavailability is only about 40%. Following oral administration, peak plasma concentrations are achieved in 1-2 hours. The mean plasma half life is in the range 2-3 hours. Penetration into the brain appears to be minimal. Following absorbtion, the drug is extensively metabolised in the liver. Both phenylephrine and its metabolites are excreted in the urine. The volume of distribution is between 200 and 500 litres, but there are no data on the extent of plasma protein binding. 5.3 Preclinical safety data There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC. 6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients Lactose, monohydrate (DC) Microcrystalline Cellulose 16
17 Powdered Cellulose Magnesium stearate Sodium starch glycollate (Type A) Silica, colloidal anhydrous Base coat (containing Macrogol 4000, Titanium dioxide E171, methacrylic acid-ethyl acrylate copolymer and Hypromellose) Colour coat (containing Hypromellose, Macrogol 4000, Talc, Azorubin E122, Brilliant Ponceau E124, Red lake E 124, Polysorbate 80) 6.2 Incompatibilities Not applicable. 6.3 Shelf life 2 years. 6.4 Special precautions for storage Do not store above 25 C. Store in the original package. 6.5 Nature and contents of container Phenylephrine Hydrochloride tablets are packed into PVC/ PVdC/ Aluminium foil blisters. Each blister consists of 12 red film coated tablets. Pack sizes: 12 or 24 tablets. 6.6 Special precautions for disposal Not applicable. 7 MARKETING AUTHORISATION HOLDER Galpharm Healthcare Ltd, Hugh House, Upper Cliffe Road Dodworth Business Park Dodworth Barnsley South Yorkshire S75 3SP 8 MARKETING AUTHORISATION NUMBER(S) PL 16028/ DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 06/02/ DATE OF REVISION OF THE TEXT 06/02/
18 PATIENT INFORMATION LEAFLET 18
19 19
20 LABELLING Carton for blisters 20
21 Generic packaging Carton for blisters 21
22 Carton showing braille only 22
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics
More informationLacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report
Lacidipine 2 mg Film-Coated Tablets PL 08553/0502 Lacidipine 4 mg Film-Coated Tablets PL 08553/0503 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken
More informationNEUROTONE THR 00904/0005 UKPAR
NEUROTONE THR 00904/0005 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Product Information Leaflet
More informationANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS
ANASTROZOLE 1 MG FILM-COATED TABLETS (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics
More informationPL 17871/0208 UKPAR TABLE OF CONTENTS
Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient
More informationMemantine hydrochloride 20 mg film-coated tablets PL 17907/0291
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics
More informationTRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR
TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4
More informationPublic Assessment Report. UK National Procedure. (colecalciferol) PL 16508/0047 PL 16508/0048. ProStrakan Ltd.
Public Assessment Report UK National Procedure STEXEROL-D 3 1,000 IU FILM-COATED TABLETS STEXEROL-D 3 25,000 IU FILM-COATED TABLETS (colecalciferol) PL 16508/0047 PL 16508/0048 ProStrakan Ltd. 1 LAY SUMMARY
More informationLEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride)
LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES (paracetamol, caffeine and phenylephrine hydrochloride) PL 00063/0529 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Summary of
More informationFexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS
Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps
More informationHYDROCORTISONE 10 MG TABLETS
HYDROCORTISONE 10 MG TABLETS (Hydrocortisone) PL 20072/0238 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary
More informationMIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS
MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Steps taken after authorisation summary
More informationUKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3
Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation Page 13 Summary of Product Characteristics
More informationHypromellose Eye Drops BP 0.3% w/v PL 23097/0006
Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient
More informationCETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS
CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 8 Steps taken after authorisation
More informationRILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS
RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Steps taken after authorisation summary
More informationDEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314
DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure TELMISARTAN DR REDDY S 20 MG TABLETS TELMISARTAN DR REDDY S 40 MG TABLETS TELMISARTAN DR REDDY S 80 MG TABLETS (telmisartan) Procedure No: UK/H/5034/001-003/DC
More informationPublic Assessment Report UKPAR
Public Assessment Report UKPAR Amitriptyline 10 mg film-coated tablets Amitriptyline 25 mg film-coated tablets Amitriptyline 50 mg film-coated tablets (Amitriptyline hydrochloride) UK Licence No: PL 17907/0131-133
More informationPublic Assessment Report
Public Assessment Report Decentralised Procedure Ibuprofen and phenylephrine hydrochloride 200mg/5mg film-coated tablets Procedure No: UK Licence No: PL 17780/0563 Winthrop Pharmaceuticals UK Limited LAY
More informationGinkgoforce Ginkgo biloba tablets THR 13668/0016 UKPAR
Ginkgoforce Ginkgo biloba tablets THR 13668/0016 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 13 Summary of product characteristics Page 14 Product
More informationAscorbic Acid 50 mg Tablets. Ascorbic Acid 100 mg Tablets. Ascorbic Acid 200 mg Tablets. Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287
Ascorbic Acid 50 mg Tablets Ascorbic Acid 100 mg Tablets Ascorbic Acid 200 mg Tablets Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287 PL 20416/0288 PL 20416/0289 UKPAR TABLE OF CONTENTS Lay Summary
More informationMACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS
MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps
More informationUrostemol Men capsules THR 02855/0240
Urostemol Men capsules THR 02855/0240 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Steps taken after initial registration Page 15 Summary of
More informationPublic Assessment Report. UK National Procedure. Perindopril 2 mg Tablets. Perindopril 4 mg Tablets. Perindopril 8 mg Tablets PL 20075/0294-0296
Public Assessment Report UK National Procedure Perindopril 2 mg Tablets Perindopril 4 mg Tablets Perindopril 8 mg Tablets PL 20075/0294-0296 Accord Healthcare Limited 1 LAY SUMMARY This is a summary of
More informationAciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR
Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for
More informationMucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665
Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient
More informationKalms Tablets THR 01074/0235 UKPAR
Kalms Tablets THR 01074/0235 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Patient Information Leaflet
More informationLevonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044
Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product
More informationSTREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES
STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES (amylmetacresol, 2,4-dichlorobenzyl alcohol, ascorbic acid and sodium ascorbate) PL 00063/0692 UKPAR TABLE
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Olopatadine Zentiva 1 mg/ml eye drops, solution (olopatadine hydrochloride) Procedure No: UK Licence No: PL 17780/0568 Winthrop Pharmaceuticals UK Limited
More informationPublic Assessment Report. Decentralised Procedure. Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated. Sildenafil citrate UK/H/4855/001-3/DC
Public Assessment Report Decentralised Procedure Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated Sildenafil citrate UK licence no: PL 08553/0468-70 DR Reddy s Laboratories (UK) Limited 1 LAY SUMMARY
More informationRELONCHEM HAYFEVER AND ALLERGY 10 MG TABLETS PL 20395/0088 UKPAR TABLE OF CONTENTS
RELONCHEM HAYFEVER AND ALLERGY 10 MG TABLETS PL 20395/0088 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken after authorisation summary
More informationPhynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR
Phynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Summary of Product Characteristics Page
More informationIbuprofen 200mg Soft Capsules PL 03105/0105 UKPAR
Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Summary of Product Characteristics Page 14 Patient
More informationOmeprazole 20 mg gastro-resistant tablets PL 14017/0277
Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation
More informationMontelukast 10mg film-coated tablets PL 17907/0474
Montelukast 10mg film-coated tablets PL 17907/0474 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation Page
More informationArnicare Arnica 30c pillules NR 01175/0181 UKPAR
Arnicare Arnica 30c pillules NR 01175/0181 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of product characteristics Page 12 Product
More informationFRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT VIRBAKOR 20 mg film-coated tablet for dogs Date: 03/11/2014 French agency for food, environnemental
More informationPublic Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.
Public Assessment Report UKPAR Levonorgestrel 1.5 mg tablet (levonorgestrel). UK Licence No: PL 41947/0006 ELC Group s.r.o. 1 LAY SUMMARY Levonorgestrel 1.5 mg tablet (Levonorgestrel, tablet, 1.5 mg) This
More informationSummary Public Assessment Report. Generics
Summary Public Assessment Report Generics 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public Assessment Report Generics Amoxicillin
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Levetiracetam 250 mg film-coated tablets PL 36390/0168; UK/H/5630/001/DC Levetiracetam 500 mg film-coated tablets PL 36390/0169; UK/H/5630/002/DC Levetiracetam
More informationSummary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy,
Summary Public Assessment Report Generics Amoxicilina + Ácido Clavulânico Ranbaxy 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public
More informationPublic Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC.
Public Assessment Report Scientific discussion Paracetamol Orifarm 500 mg film-coated tablets (Paracetamol) DK/H/2271/001/DC 15 October 2014 This module reflects the scientific discussion for the approval
More informationPublic Assessment Report. Decentralised Procedure. Cefuroxime 250mg and 500mg film-coated tablets. Cefuroxime 500mg film-coated tablets
Public Assessment Report Decentralised Procedure Cefuroxime 250mg film-coated tablets Cefuroxime 500mg film-coated tablets Procedure No: UK Licence No: PL 35646/0020-0021 Alkem Pharma GmbH 1 LAY SUMMARY
More informationPHENYLEPHRINE HYDROCHLORIDE INJECTION USP
PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada
More informationSODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS
SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Steps taken after authorisation
More informationCETRABEN ORIGINAL EMOLLIENT CREAM (PL 06831/0262) UKPAR TABLE OF CONTENTS
CETRABEN ORIGINAL EMOLLIENT CREAM (PL 06831/0262) UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary Page
More informationCODEINE PHOSPHATE 15 MG TABLETS CODEINE PHOSPHATE 30 MG TABLETS CODEINE PHOSPHATE 60 MG TABLETS PL 24837/0023-5 UK PAR TABLE OF CONTENTS
CODEINE PHOSPHATE 15 MG TABLETS CODEINE PHOSPHATE 30 MG TABLETS CODEINE PHOSPHATE 60 MG TABLETS PL 24837/0023-5 UK PAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for
More informationPublic Assessment Report
Public Assessment Report Decentralised Procedure Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion Procedure No: UK Licence No: PL 24598/0029 Noridem Enterprises Limited LAY SUMMARY On 25 January
More informationSalbutamol 1mg/ml Nebuliser Solution. Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036
Salbutamol 1mg/ml Nebuliser Solution Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment
More informationPublic Assessment Report. Decentralised Procedure. Cefadroxil 250 mg/5 ml granules for oral. (Cefadroxil monohydrate)
Public Assessment Report Decentralised Procedure Cefadroxil 250 mg/5 ml granules for oral suspension (Cefadroxil monohydrate) UK licence no: PL 34088/0033 Alkaloid-INT d.o.o. 1 Cefadroxil 250 mg/5 ml granules
More informationPublic Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680
Public Assessment Report Scientific discussion Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680 This module reflects the scientific discussion for the approval of
More informationBeclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178
Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 11 Steps Taken
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure PERRIGO PARACETAMOL/GUAIFENESIN/PHENYLEPHRINE HYDROCHLORIDE 500 MG/200 MG/10 MG POWDER FOR ORAL SOLUTION UK Licence No: PL 12063/0118 WRAFTON LABORATORIES
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Linezolid 2 mg/ml solution for infusion Linezolid 600mg film coated tablets Linezolid 100mg/5ml granules for oral suspension Procedure No: UK Licence No:
More informationISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS
ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken after authorisation
More informationPublic Assessment Report. Decentralised Procedure PARACETAMOL 1000 MG TABLETS. Procedure No: UK/H/5004/01/DC. UK Licence No: PL 18866/0060
Public Assessment Report Decentralised Procedure PARACETAMOL 1000 MG TABLETS Procedure No: UK Licence No: PL 18866/0060 Rockspring Healthcare Ltd LAY SUMMARY On 17 January 2013 the Medicines and Healthcare
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Amlodipine Pfizer 5 mg tablets Amlodipine Pfizer 10 mg tablets Amlodipine Pfizer 5 mg hard capsules Amlodipine Pfizer 10 mg hard capsules Procedure No:
More informationPublic Assessment Report Scientific discussion. Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC
Public Assessment Report Scientific discussion Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC This module reflects the scientific discussion for the approval of Levetiracetam Krka. The procedure
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Trihexyphenidyl 2mg Tablets BP 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg of trihexyphenidyl hydrochloride BP
More informationPARACETAMOL 500MG TABLETS B.P. (PARACETAMOL) PL 17907/0146 UKPAR TABLE OF CONTENTS
PARACETAMOL 500MG TABLETS B.P. (PARACETAMOL) PL 17907/0146 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken after authorisation Page
More informationPublic Assessment Report. Scientific discussion. Desloracell 5 mg, film-coated tablet. (desloratadine) NL License RVG: 112807
Public Assessment Report Scientific discussion Desloracell 5 mg, film-coated tablet (desloratadine) NL License RVG: 112807 Date: 6 July 2015 This module reflects the scientific discussion for the approval
More informationNEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate.
NEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate. PRESENTATION Eye Drops: NAPHCON-A Eye Drops are a combination of an antihistamine (pheniramine maleate) and a decongestant
More informationWhite, circular, biconvex, uncoated tablets with a score line on one side, plain on the other.
Nausicalm Cyclizine hydrochloride Ph. Eur. 50 mg Presentation White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. Uses Actions The active ingredient-cyclizine
More information4 Clinical Particulars
SUMMARY OF PRODUCT CHARACTERISTICS 1 Name of the Medicinal Product Procyclidine Syrup 5mg/5ml 2. Qualitative and Quantitative Composition Each 5ml dose contains 5mg Procyclidine Hydrochloride BP. 3. Pharmaceutical
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure FOSFOMYCIN 3G GRANULES FOR ORAL SOLUTION Procedure No: UK Licence No: PL 31513/0007 Temapharm Sp. z.o.o. LAY SUMMARY On 17 April 2013, Czech Republic, Estonia,
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125
More informationPublic Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921
Public Assessment Report Scientific discussion Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921 This module reflects the scientific discussion for the approval of
More informationLOPERAMIDE 2MG TABLETS. (Loperamide hydrochloride) PL 20117/0087 UKPAR TABLE OF CONTENTS
LOPERAMIDE 2MG TABLETS (Loperamide hydrochloride) PL 20117/0087 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation
More informationPublic Assessment Report. Decentralised Procedure. CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution
Public Assessment Report Decentralised Procedure CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution (Macrogol, sodium chloride, sodium hydrogen carbonate
More informationPublic Assessment Report. Scientific discussion. Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007
Public Assessment Report Scientific discussion Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007 Applicant: E Consult ApS, Denmark This module reflects the
More informationPublic Assessment Report. Scientific discussion. Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676. Applicant: E Consult ApS, Denmark
Public Assessment Report Scientific discussion Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676 Applicant: E Consult ApS, Denmark This module reflects the scientific discussion for the approval
More informationIbuprofen 10% w/w gel Nurofen Maximum Strength 10 % Gel
Ibuprofen 10% w/w gel Nurofen Maximum Strength 10 % Gel PL 10972/0089 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics
More informationParamed/Boots Max Strength Sinus Relief Day & Night Capsules (PL 12063/0074)
Paramed/Boots Max Strength Sinus Relief Day & Night Capsules (PL 12063/0074) UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Steps taken after
More informationPublic Assessment Report. (Budesonide) PL 17901/0254. AstraZeneca UK Ltd
Public Assessment Report Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) PL 17901/0254 AstraZeneca UK Ltd 1 LAY SUMMARY Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) This is a
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE)
European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMEA/HMPC/745582/2009 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH
More informationAdrenaline (epinephrine) 1:1000 Injection BP Summary of Product Characteristics
Adrenaline (epinephrine) 1:1000 Injection BP Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Adrenaline (epinephrine) 1:1000 Injection BP 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationPublic Assessment Report. Decentralised Procedure. Tenofovir Zentiva 245 mg Film-coated Tablets. Tenofovir disoproxil fumarate UK/H/4970/001/DC
Public Assessment Report Decentralised Procedure Tenofovir Zentiva 245 mg Film-coated Tablets Tenofovir disoproxil fumarate UK licence no: PL 17780/0573 Winthrop Pharmaceuticals UK Limited 1 LAY SUMMARY
More informationPANADOL OA 1000MG TABLETS PL 00071/0456 UKPAR TABLE OF CONTENTS
PANADOL OA 1000MG TABLETS PL 00071/0456 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 13 Steps taken after authorisation summary Page 14 Summary
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Atorvastatin 10 mg film-coated Tablets Atorvastatin 20 mg film-coated Tablets Atorvastatin 40 mg film-coated Tablets Atorvastatin 80 mg film-coated Tablets
More informationCO-CODAMOL 30MG/500MG TABLETS PL 17907/0235 UKPAR TABLE OF CONTENTS
CO-CODAMOL 30MG/500MG TABLETS PL 17907/0235 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken after authorisation summary Page 12 Summary
More informationJANUVIA sitagliptin phosphate 25 mg, 50 mg & 100 mg tablets
JANUVIA sitagliptin phosphate 25 mg, 50 mg & 100 mg tablets What is in this leaflet This leaflet answers some common questions about JANUVIA. It does not contain all the available information. It does
More informationPublic Assessment Report. Decentralised Procedure. Alimemazine tartrate 7.5mg/5ml Syrup. Alimemazine tartrate 30mg/5ml Syrup
Public Assessment Report Decentralised Procedure Alimemazine tartrate 7.5mg/5ml Syrup Alimemazine tartrate 30mg/5ml Syrup Procedure No: UK Licence No: PL 41830/0029-0030 NRIM Limited 1 LAY SUMMARY Alimemazine
More informationSR 5. W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1
W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1 alfuzosin SR 5 mg (Alfuzosin HCI) COMPOSITION Each sustained-release, film-coated tablet contains: Alfuzosin hydrochloride......... 5 mg Excipients... q.s.
More informationMEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets
MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants) and other psychiatric
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully before you start using this
More informationLOPERAMIDE 2MG TABLETS. (Loperamide hydrochloride) PL 33410/0023 PL 33410/0063 UKPAR TABLE OF CONTENTS
LOPERAMIDE 2MG TABLETS (Loperamide hydrochloride) PL 33410/0023 PL 33410/0063 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after
More informationPackage Leaflet: Information for the user Propecia 1 mg film-coated Tablets Finasteride
Package Leaflet: Information for the user Propecia 1 mg film-coated Tablets Finasteride This medicine is for use in men only Read all of this leaflet carefully before you start taking this medicine because
More informationMEDICATION GUIDE KOMBIGLYZE XR (kom-be-glyze X-R) (saxagliptin and metformin HCl extended-release) tablets
MEDICATION GUIDE KOMBIGLYZE XR (kom-be-glyze X-R) (saxagliptin and metformin HCl extended-release) tablets Read this Medication Guide carefully before you start taking KOMBIGLYZE XR and each time you get
More information1 What Anapen is and what it is used for?
PACKAGE LEAFLET: INFORMATION FOR THE USER Anapen 500 micrograms in 0.3 ml solution for injection (pre-filled syringe) Adrenaline (Epinephrine) Auto-Injector Read all of this leaflet carefully before you
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (HCl) STEROP 0,8mg/1ml. Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (HCl) STEROP 0,4mg/1ml ADRENALINE (HCl) STEROP 0,8mg/1ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully
More informationPublic Assessment Report Scientific discussion. Tenofovir disoproxil Teva (tenofovir disoproxil) SE/H/1432/01/DC
Public Assessment Report Scientific discussion Tenofovir disoproxil Teva (tenofovir disoproxil) SE/H/1432/01/DC This module reflects the scientific discussion for the approval of Tenofovir disoproxil Teva.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Progit 50 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 50 mg of itopride hydrochloride.
More informationPublic Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules
Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: 111783 Date: 12 March 2015 This
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Librium 10mg Hard capsule Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 10 mg of chlordiazepoxide hydrochloride. Excipients:
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure IMATINIB TEVA UK 100 MG FILM-COATED TABLETS IMATINIB TEVA UK 400 MG FILM-COATED TABLETS (imatinib mesilate) Procedure No: UK Licence No: PL 00289/1516-1517
More informationPublic Assessment Report. Table of Contents
Public Assessment Report Lidocaine Injection BP with preservative 1% Lidocaine Injection BP with preservative 2% PL 01502/0070 PL 01502/0071 Hameln Pharmaceuticals Limited Table of Contents Page Lay Summary
More informationPublic Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498
Public Assessment Report Scientific discussion Prednisolon Pilum (prednisolone) Asp no: 2013-0498 This module reflects the scientific discussion for the approval of Prednisolon Pilum. The procedure was
More informationDecentralised Procedure. Public Assessment Report
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report ben-u-ron direkt Erdbeer/Vanille 250/500 mg Granulat in Beuteln ben-u-ron direkt Cappuccino 500/1000
More information